Company Overview of Forest Laboratories, LLC
Forest Laboratories, LLC develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Its products include Fetzima and Viibryd for the treatment of major depressive disorder; Linzess to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Tudorza Pressair, an antimuscarinic agent for the treatment of bronchospasm associated with chronic obstructive pulmonary disease. The company also provides Namenda IR and Namenda XR for moderate to severe dementia of the Alzheimer’s type; Daliresp, a phosphodiesterase-4 enzyme inhibitor to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patien...
909 Third Avenue
New York, NY 10022
Founded in 1954
Key Executives for Forest Laboratories, LLC
Senior Vice President of Operations
Chief Executive of Forest Laboratories - Europe
Principal Accounting Officer, Vice President and Controller
Chief Compliance Officer and Senior Vice President
Senior Vice President of Sales for Forest Laboratories
Compensation as of Fiscal Year 2015.
Forest Laboratories, LLC Key Developments
Glenmark Pharmaceuticals and Glenmark Pharmaceuticals Inc., USA Enter into Settlement Agreement with Forest Laboratories, LLC, Forest Laboratories Holdings and Royalty Pharma Collection Trust
Dec 21 15
Glenmark Pharmaceuticals and Glenmark Pharmaceuticals Inc., USA, have entered into a Settlement Agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismiss the outstanding patent litigation related to Glenmark's Abbreviated New Drug Application for Milnacipran Hydrochloride 12.5 milligram, 25 milligram, 50 milligram, and 100 milligram tablets, the generic version of Forest's Savella. Under the terms of the Settlement Agreement, Glenmark will have the option to market and distribute its Milnacipran Hydrochloride tablets or an authorized generic version of Savella tablets.
Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc. Enter into a Settlement Agreement with Amneal Pharmaceuticals LLC and Related Companies and Subsidiaries
Sep 10 15
Allergan plc announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries. The settlement relates to a patent infringement litigation brought by Forest and Adamas in response to Amneal's abbreviated new drug application (ANDA) seeking approval to market generic versions of Allergan's NAMENDA XR(R) (memantine hydrochloride) extended release capsules. It is Allergan's understanding that Amneal is the first applicant to file an ANDA containing a paragraph IV certification regarding NAMENDA XR. Specifically, under the terms of the settlement agreement, and subject to review of the settlement terms by the U.S. Federal Trade Commission, Forest and Adamas will grant Amneal a license to market generic versions of NAMENDA XR beginning on January 31, 2020, following receipt by Amneal of final approval from the U.S. Food and Drug Administration (FDA) on its ANDA for generic NAMENDA XR. Alternatively, under certain circumstances, Amneal has an option to launch an authorized generic version of NAMENDA XR(R) beginning on January 31, 2021. Other terms of the settlement were not disclosed. Similar patent infringement litigations brought by Forest, Adamas and Merz Pharma GmnH & Co. KgaA, against certain other companies that have filed ANDAs seeking approval to market generic versions of NAMENDA XR remain pending in the U.S. District Court for the District of Delaware. Allergan is committed to Alzheimer's patients and caregivers through the Company's continued support of NAMENDA XR, as well as the recent introduction of a new innovative treatment option, NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride).
U.S. District Court Certifies Female Sales Representatives' Equal Pay Act Class Suit against Forest Laboratories Inc
Sep 3 15
The Plaintiffs in Barrett et al. v. Forest Laboratories Inc. secured win when Magistrate Judge Michael Dolinger granted collective action certification to a class of female pharmaceutical sales representatives currently and formerly employed by Forest Laboratories (acquired in 2014 by Actavis). After reviewing voluminous briefing from the Parties, Judge Dolinger concluded that the thousands of women who work or worked at Forest between June 17, 2009 and the present should receive Court-ordered notice about their opportunity to participate in a class action challenging pay discrimination at Forest. The decision came down late on Sept. 2. The Court issued this ruling over the vigorous opposition of Forest, which anticipated annual revenues of over $15 billion for 2015 after its acquisition by Actavis was completed in July 2014. In issuing his ruling in favor of Plaintiffs, Judge Dolinger noted that Plaintiffs' expert had identified 'a statistically significant difference between the pay of male and female Sales Representatives' at Forest.
Similar Private Companies By Industry
Recent Private Companies Transactions